Research Article
Characteristics, Outcomes, and Cost Patterns of High-Cost Patients in the Intensive Care Unit

Peter M. Reardon,1,2 Shannon M. Fernando,1,2 Sasha Van Katwyk,3 Kednapa Thavorn,3,4,5 Daniel Kobewka,3,6 Peter Tanuseputro,3,4,5,6,7 Erin Rosenberg,1 Cynthia Wan,5 Brandi Vanderspank-Wright,3,9 Dalibor Kubelik,1,3,10 Rose Anne Devlin,11 Christopher Klinger,12 and Kwadwo Kyeremanteng1,3,7

1Division of Critical Care Medicine, University of Ottawa, Ottawa, ON, Canada
2Department of Emergency Medicine, University of Ottawa, Ottawa, ON, Canada
3Ottawa Hospital Research Institute, Ottawa, ON, Canada
4School for Clinical and Evaluative Sciences, University of Ottawa, Ottawa, ON, Canada
5Institute for Clinical and Evaluative Sciences, University of Ottawa, Ottawa, ON, Canada
6Department of Medicine, University of Ottawa, Ottawa, ON, Canada
7Division of Palliative Care Medicine, University of Ottawa, Ottawa, ON, Canada
8School of Psychology, University of Ottawa, Ottawa, ON, Canada
9School of Nursing, University of Ottawa, Ottawa, ON, Canada
10Division of Vascular Surgery, University of Ottawa, Ottawa, ON, Canada
11Department of Economics, University of Ottawa, Ottawa, ON, Canada
12Factor-Inwentash, Faculty of Social Work, University of Toronto, Toronto, ON, Canada

Correspondence should be addressed to Peter M. Reardon; prear074@uottawa.ca

Received 9 April 2018; Revised 26 June 2018; Accepted 16 July 2018; Published 2 September 2018

Background. ICU care is costly, and there is a large variation in cost among patients. Methods. This is an observational study conducted at two ICUs in an academic centre. We compared the demographics, clinical data, and outcomes of the highest decile of patients by total costs, to the rest of the population. Results. A total of 7,849 patients were included. The high-cost group had a longer median ICU length of stay (26 versus 4 days, \( P < 0.001 \)) and amounted to 49% of total costs. In-hospital mortality was lower in the high-cost group (21.1% versus 28.4%, \( P < 0.001 \)). Fewer high-cost patients were discharged home (23.9% versus 45.2%, \( P < 0.001 \)), and a large proportion were transferred to long-term care (35.1% versus 12.1%, \( P < 0.001 \)). Patients with younger age or a diagnosis of subarachnoid hemorrhage, acute respiratory failure, or complications of procedures were more likely to be high cost. Conclusions. High-cost users utilize half of the total costs. While cost is associated with LOS, other drivers include younger age or admission for respiratory failure, subarachnoid hemorrhage, or after a procedural complication. Cost-reduction interventions should incorporate strategies to optimize critical care use among these patients.

1. Background

Care provided in the Intensive Care Unit (ICU) is expensive. On average, the daily cost of an ICU bed is threefold higher than a bed in a general ward [1]. Overall, critical care accounts for a significant portion of health care costs, as 11% of hospital admissions now incorporate a stay in the ICU [1]. Additionally, ICU costs are expected to rise due to an aging population and the increasing severity of illness among hospitalized patients [2, 3]. Recent data reveal a 12% increase in ICU utilization over a 6-year period, with up to one-third of these patients requiring invasive mechanical ventilation [1]. This escalating demand for critical care places financial strain on
health care systems, prompting the need for strategies to mitigate costs.

It has been well described in the literature that a small proportion of patients account for a disproportionate amount of health care spending [4–10]. Identifying and describing these patients may present an opportunity for focused interventions to reduce spending. However, there is a paucity of literature describing the characteristics of these patients in the general ICU setting [11, 12]. Welton et al. retrospectively examined a cohort of adult ICU patients admitted to a single academic centre in the United States [11]. Although they separated out the top decile of high-resource users and described total costs, their study did not categorize costs or outline the specific use of resources. They did not perform any regression analysis to determine what patient factors are associated with high cost.

This study aims to further describe high-cost users in the ICU by identifying patient factors, cost patterns, and outcomes associated with high cost. A better understanding of the high-resource user may help care providers anticipate resource demands and provide an opportunity to implement interventions to reduce costs without compromising the quality of care.

2. Methods

This is a retrospective observational cohort study conducted with the approval of the Ottawa Health Science Network Research Ethics Board.

2.1. Study Population. The Ottawa Hospital (TOH) is a tertiary care, academic health sciences hospital, which serves as a referral centre for approximately 1.3 million people in Eastern Ontario, Canada. There are two tertiary care ICUs with 28 beds at each site. The ICU at TOH is a closed model, requiring consultation with an intensivist prior to admission. Discharge planning is conducted as a team approach, requiring approval from the attending intensivist, as well as acceptance from a consulting service who assumes responsibility once the patient is discharged. Upon discharge, the ICU team conducts routine follow-up until the patient is deemed stable by the intensivist.

The study population included all adult patients with at least one admission to an ICU at The Ottawa Hospital between January 1, 2011, and December 31, 2014. For patients with more than one hospital admission with an ICU stay during the study period, only the outcomes and cost for the first admission were considered. The patients were followed up for the length of their hospitalization until discharge or up to one year (whichever comes first), which included any transfers out of or back into the ICU. The one-year limit was added to reduce the weighted effect of prolonged individual admissions on study data.

2.2. Data Sources. All data for the study were obtained from the Data Warehouse at The Ottawa Hospital. The Data Warehouse contains information from several information systems including the patient registration system, clinical data repository, case-costing system, and patient abstracts for multiple encounter types [13]. Case costing at The Ottawa Hospital is determined using the system developed by the Ontario Case Costing Initiative [14], based on the Canadian Institute for Health Information Management Information Systems Guidelines [15]. The case-costing system provides detailed information regarding the direct and indirect costs incurred by each patient during their admission.

Direct costs are all expenses to the hospital with fee codes linked to the patient chart, including salaries and benefits for the unit producing and management staff, equipment, and screening and procedure materials. The Data Warehouse uses a unit value of cost per minute of service for all staff, materials, and equipment within the hospital and calculates the direct cost according to the time it was utilized for the patient. Indirect costs are any overhead operational fees associated with the service being provided to the patient such as the cost of the room they occupy per hour. External care facilities costs to which patients may be discharged were not included in this analysis. All costs are reported in Canadian dollars (CDN).

2.3. Variables. From the Data Warehouse, we used the patient registry file and hospital abstracts to determine the demographic and clinical characteristics of included patients. We obtained detailed admission data from the hospital discharge abstracts including admission and discharge dates, length of stay (LOS), level of care provided (ward versus ICU), most responsible diagnosis (MRDx), and disposition. Hospital discharge abstracts were also used to identify previous ICU and Emergency Department (ED) encounters within the 12 months before the index admission. Comorbid conditions were summarized and presented as the Elixhauser comorbidity index [16, 17], which uses coded information based on the International Classification of Diseases, Version 10 (ICD-10-CA). These data are collected and coded routinely for every admission by the health records department. Patients with missing data were excluded from the analysis.

Patients were characterized as either “high cost” or “non-high cost.” The high-cost group was defined as the top 10% of patients incurring the largest total (direct and indirect) admission costs. The primary objective of this study was to compare the high-cost users to the remaining 90% of patients according to patient characteristics, primary diagnoses, and comorbidity score.

2.4. Statistical Analysis. Patient demographics such as age, sex, and Elixhauser comorbidity score, as well as the disposition (e.g., home, acute care transfer, and long-term care transfer) and MRDx, in the high-cost and non-high-cost groups were compared using the chi-square test or Fisher’s exact test, with the level of significance of 0.05. Continuous variables were assessed with the Mann–Whitney U test. Age was categorized into four categories: aged 18 to 45, 46 to 69, 70 to 79, and 80 or older. Univariate analyses were conducted to compare patient characteristics between the
high-cost cohort and the remaining 90% of patients. Cost was calculated by total costs, indirect and direct costs, as well as a cost breakdown to view the components responsible for the cost of the high-cost and non-high-cost groups.

We also performed a multivariate logistic regression to determine factors associated with the high-cost status and estimated an adjusted odds ratio (OR). The inclusion of variables in the regression analysis was guided by previous studies and subject to availability of the variables in our database. Our regression model included age category, sex, Elixhauser comorbidity score, and MRDx. We performed a subgroup analysis of patients who died during hospitalization using the same logistic regression approach.

3. Results

There were 7,849 patients admitted to the ICU during the four-year study period with 786 in the high-cost group and 7,063 in the non-high-cost group. Direct costs, representing approximately 75% of total costs for the study period, had a median value of $148,328 (IQR $114,008–$224,611) in the high-cost group, compared to $20,407 (IQR $10,977–$37,750) in the non-high-cost group. The characteristics of the included study patients are presented in Table 1. The mean age was 60.7 years (SD 16.3) in the high-cost group and 62.3 years (SD 17.3) in the non-high-cost group (P = 0.012). The age categories 18–45, 46–69, and 70–79 were similar between groups; however, there were fewer patients aged greater than 80 years in the high-cost group (10.8% versus 16.4%, P = 0.007). There were high rates of congestive heart failure (14.8 versus 9.1, P < 0.001), chronic obstructive pulmonary disease (19.0 versus 12.4, P < 0.001), and baseline renal failure (8.9 versus 5.3, P < 0.001) in the high-cost group. Sex and the number of Emergency Department visits within the preceding 12 months were similar between groups. There were statistically more ICU encounters in the preceding 12 months in the high-cost group (1.3 versus 1.0, P < 0.001). For the high-cost group, the median total LOS was 68 days (IQR 49–103) versus 10 days (IQR 4–20) for the non-high-cost group. A median of 26 days (IQR 17–38) were spent in the ICU in the high-cost group compared to 4 (IQR 2–8) ICU days for those in the non-high-cost group (P < 0.001).

In terms of disposition, only 23.9% of patients in the high-cost cohort were ultimately discharged directly home from hospital, compared to 45.2% in the non-high-cost group (P < 0.001). A large proportion of high-cost patients, 35.1%, were transferred from hospital to long-term care, relative to 12.1% in the non-high-cost group (P < 0.001). In-hospital mortality was significantly lower in the high-cost cohort at 21.1%, compared to 28.4% of the non-high-cost group (P < 0.001).

Hospita, costs are shown in Table 2. The high-cost group was responsible for 49% percent of total costs. Direct costs had a median value of $148,328 (IQR $114,008–$224,611) in the high-cost group, compared to $20,407 (IQR $10,977–$37,750) in the non-high-cost group. The mean cost per day was also significantly increased in the high-cost group $3645 (SD 1915), relative to the non-high-cost group $3327 (SD 2159) (P < 0.001). Cost breakdown shows the highest proportion of cost is generated from the ICU and nursing care for both groups.

The results of the multivariate logistic regression (Table 3) show that compared to patients aged 18–45, all older age categories are less likely to be in the high-cost group. When compared to patients sent home, patients are more likely to be high-resource users if they were transferred out of ICU to an inpatient acute care setting (adjusted OR 2.49, 95% CI 2.02–3.08). Conversely, patients who died were less likely to be in the high-resource group (adjusted OR 0.65, 95% CI 0.52–0.81). Patients transferred to continuing care were of similar likelihood between cost groups. With regard to MRDx, patients admitted with ischemic stroke (adjusted OR 0.53, 95% CI 0.29–0.99), heart failure (adjusted OR 0.39, 95% CI 0.29–0.99), or AAA and dissection (adjusted OR 0.60, 95% CI 0.41–0.87), or with an overdose (adjusted OR 0.08, 95% CI 0.02–0.34) were significantly less likely to be within the high-resource group. Patients with an MRDx of acute respiratory failure (adjusted OR 2.44, 95% CI 1.88–3.18), subarachnoid hemorrhage (adjusted OR 2.18, 95% CI 1.47–3.24), complications of procedures (adjusted OR 1.80, 95% CI 1.33–2.44), malignancy (adjusted OR 1.56, 95% CI 1.23–1.98), or sepsis (adjusted OR 1.55, 95% CI 1.26–1.91) were more likely to be in the high-cost group.

Among decedents (Table 4), when compared to patients aged 18–45 years, patients aged greater than 80 years were less likely to be in the high-cost group (adjusted OR 0.37, 95% CI 0.28–0.50). Sex and Elixhauser comorbidity score were not associated with the high-cost status in the regression model. Patients with an MRDx of traumatic intracranial injury were less likely to be in the high-cost group (adjusted OR 0.25, 95% CI 0.08–0.82), while patients with complications of procedures (OR 2.85, 95% CI 1.52–5.33), acute respiratory failure (OR 2.25, 95% CI 1.37–3.68), malignancy (OR 1.65, 95% CI 1.23–2.15), or overdose (OR 0.53, 95% CI 0.29–0.99), were more likely to be in the high-cost group. There were no deaths among high-cost patients with an MRDx of acute ischemic stroke or an overdose.

4. Discussion

This is a retrospective study conducted at a large academic centre to examine the demographics, characteristics, and outcomes of high-cost users in the ICU. In our analysis, the top 10% of high-cost users amounted to 49% of total costs. ICU LOS and hospital LOS were significantly longer in the high-cost group. Younger age was significantly associated with high cost. Although high-cost users were less likely to be discharged home, they were also less likely to die, with the highest proportion being discharged to long-term care, and an MRDx of subarachnoid hemorrhage (SAH), acute respiratory failure (ARF), and complications of procedures had the strongest association with high cost, while an MRDx of ischemic stroke, heart failure, and overdose was the least costly.

Similar to the previous literature [18–20], LOS appears to be a major driver of high cost in this study as reflected by the substantially longer acute length of stay in the high-cost
Currently in Ontario, the average daily cost in the ICU at a teaching hospital is $4,186, while an acute care bed is valued at $1,492 per day [1]. The magnitude of cost difference between levels of care highlights the critical importance of patient flow within the hospital and also appropriate use of specialty care units to maximize the utility of hospital resources and reduce overall costs [21, 22]. Providing critical care outside of the ICU has been proposed as a solution to facilitate early discharge and avoid unnecessary admissions. However, recent discussions have had mixed reviews, and definitive evidence is lacking [21, 23].

In addition, cost per day was significantly higher for the high-cost group. As an MRDx of ARF and SAH was most strongly associated with high cost, it is likely that daily cost was influenced by the type of interventions and support

| Table 1: Patient characteristics. | High cost \((n = 786)\) | Non-high cost \((n = 7063)\) | \(P\) value |
|---------------------------------|--------------------------|---------------------------|-------------|
| **Age, mean years (SD)**        | 60.7 (16.3)              | 62.3 (17.3)               | 0.012       |
| Category (%)                    |                          |                           |             |
| 18–45                           | 17.3                     | 15.9                      | 0.274       |
| 46–69                           | 51.2                     | 46.3                      | 0.113       |
| 70–79                           | 20.7                     | 21.4                      | 0.845       |
| 80+                             | 10.8                     | 16.4                      | 0.007       |
| Sex, male                       | 59.6                     | 56.1                      | 0.063       |
| Elixhauser comorbidity score (total) | 6.12                    | 5.28                      | <0.001     |
| Congestive heart failure        | 14.8                     | 9.1                       | <0.001     |
| Pulmonary circulation disorder  | 5.6                      | 3.5                       | 0.003       |
| Peripheral vascular disorder    | 10.1                     | 10.8                      | 0.527       |
| Chronic obstructive pulmonary disease | 19.0                  | 12.4                      | <0.001     |
| Diabetes                        | 25.7                     | 26.4                      | 0.658       |
| Renal failure                   | 8.9                      | 5.3                       | <0.001     |
| Liver disease                   | 6.6                      | 5.4                       | 0.185       |
| Metastatic cancer               | 5.5                      | 7.2                       | 0.075       |
| Solid tumour without metastases | 13.3                     | 13.3                      | 0.988       |
| Emergency Department visits within 12 months, mean | 3.1                      | 2.8                       | 0.201       |
| Intensive Care Unit admissions within 12 months, mean | 1.3                      | 1.0                       | <0.001     |
| **LOS, median days (IQR)**      |                          |                           |             |
| Acute LOS                       | 38 (17–74)               | 4 (1–11)                  | <0.001     |
| ICU LOS                         | 26 (17–38)               | 4 (2–8)                   | <0.001     |
| Total LOS                       | 68 (49–103)              | 10 (4–20)                 | <0.001     |
| Disposition (%)                 |                          |                           |             |
| Home                            | 23.9                     | 45.2                      | <0.001     |
| Signed out against medical advice | 0.1                     | 0.7                       | 0.029       |
| Transferred to acute care       | 21.1                     | 13.9                      | 0.003       |
| Transferred to long-term care   | 35.1                     | 12.1                      | <0.001     |
| In-hospital mortality           | 21.1                     | 28.4                      | <0.001     |
| **In-hospital mortality**       |                          |                           |             |
| Home                            | 23.9                     | 45.2                      | <0.001     |
| Signed out against medical advice | 0.1                     | 0.7                       | 0.029       |
| Transferred to acute care       | 21.1                     | 13.9                      | 0.003       |
| Transferred to long-term care   | 35.1                     | 12.1                      | <0.001     |
| In-hospital mortality           | 21.1                     | 28.4                      | <0.001     |

\(SD\): standard deviation; \(LOS\): length of stay; \(IQR\): interquartile range.

| Table 2: Cost comparison by high-cost status (Canadian dollars (CDN)). | High cost \((N = 786)\) | Non-high cost \((N = 7063)\) | \(P\) value |
|------------------------------------------------------------------------|--------------------------|---------------------------|-------------|
| **Total cost per patient, median CDN (IQR)**                           | 196,766                  | 27,120                    |             |
| Direct cost per patient, median CDN (IQR)                              | 148,328 (114,008–224,611) | 20,407 (10,977–37,750)  |             |
| Cost per day, median CDN (IQR)                                         | 3,213 (2,313–4,549)      | 2,883 (2,079–3,919)      | <0.001     |
| Cost per day, mean CDN (SD)                                            | 3,645 (1,915)            | 3,327 (2,159)            | <0.001     |
| **Direct cost allocation (%)**                                        |                          |                           |             |
| Endoscopy                                                              | 0.2                      | 0.2                       |             |
| Food services                                                          | 2.2                      | 2.1                       |             |
| Health professional services                                          | 3.4                      | 2.4                       |             |
| Imaging                                                                | 2.8                      | 3.8                       |             |
| Laboratory                                                             | 4.0                      | 5.6                       |             |
| Nursing                                                                | 36.4                     | 24.8                      |             |
| Operating room                                                         | 2.0                      | 5.4                       |             |
| Pharmacy                                                               | 7.5                      | 5.4                       |             |
| Postanaesthetic care unit                                             | 0.2                      | 0.5                       |             |
| Intensive Care Unit                                                    | 41.3                     | 49.6                      |             |

\(SD\): standard deviation; \(IQR\): interquartile range.
with high cost among all patients. Higher costs [25]. Complex neuroimaging and procedural therapy which drive cost for ARF patients, while the care of SAH requires contribution to ICU costs [20, 24], leading to higher daily literature that mechanical ventilation is of noteworthy required for their treatment. It has been well described in the literature that mechanical ventilation is of noteworthy contribution to ICU costs [20, 24], leading to higher daily cost for ARF patients, while the care of SAH requires complex neuroimaging and procedural therapy which drive higher costs [25].

In this study, complications of procedures demonstrated a strong association with high cost. The association was stronger when only decedents were assessed. The high cost associated with procedural complications, particularly surgical complications, has been well documented in the literature with often substantial increases in costs [26–28]. Causes of this are unclear, but possibly a sense of responsibility from the physician can lead to persistent patient care at times when it is no longer indicated. Further study is warranted in order to explore how the development of targeted investigations, such as earlier palliative care consultation [29–31], may benefit these patients and reduce ICU costs.

Overall, mortality was lower for the high-cost group. This is in contrast to previous studies demonstrating increased costs among those dying in the ICU [24]. As cost appears to be heavily influenced by LOS, those with severe pathologies may have died sooner, reducing their impact on costs. Conversely, our high-cost group was younger. Patients aged greater than 80 years were the least likely to be associated with high cost. This may have impacted our mortality rates as advanced age has been linked to higher mortality rates [32, 33]. Interestingly, this association of younger age and high cost has not been previously demonstrated. Other studies have shown either no association or a trend towards increasing costs for older patients [12, 34]. Although not significant, the other (non-ICH) trauma groups trended increasing costs for older patients [12, 34]. Although not significant, the other (non-ICH) trauma groups trended towards higher costs. A younger cohort of patients with traumatic injuries requiring surgical intervention and prolonged recovery may explain these findings.

5. Limitations
This is a database study with limited patient-level information. Future studies with more detailed data on medical comorbidities and their severity and interventions provided during hospitalization would help identify targets for cost-reduction strategies. Unfortunately, illness severity scores (e.g., APACHE and SAPS) were not available in our database and could not be included for comparison between groups. It should also be noted that regression analysis of

| Characteristics                          | OR   | 95% confidence intervals | P value |
|------------------------------------------|------|--------------------------|---------|
| Age                                      |      |                          |         |
| 18–45                                    | 1.00 |                          |         |
| 46–69                                    | 0.95 | 0.81–1.12                | <0.001  |
| 70–79                                    | 0.83 | 0.70–0.98                | <0.001  |
| 80+                                      | 0.67 | 0.50–0.89                | <0.001  |
| Sex                                      |      |                          |         |
| Male                                     | 1.23 | 1.00–1.42                | 0.016   |
| Female                                   |      |                          |         |

| Discharge disposition                    |      |                          |         |
| Home                                     |      |                          |         |
| Transfer acute care                      | 2.49 | 2.02–3.08                | <0.001  |
| Transfer continuing care                 | 1.59 | 0.70–3.61                | 0.263   |
| In-hospital mortality                    | 0.65 | 0.52–0.81                | <0.001  |
| Elixhauser comorbidity score             | 1.02 | 1.00–1.03                | 0.006   |
| Elixhauser comorbidity score (total)     |      |                          |         |
| Most responsible diagnosis               |      |                          |         |
| Sepsis                                   | 1.55 | 1.26–1.91                | <0.001  |
| Malignancy                               | 1.56 | 1.23–1.98                | <0.001  |
| Subarachnoid hemorrhage                  | 2.18 | 1.47–3.24                | <0.001  |
| Other nontraumatic ICH                   | 0.95 | 0.55–1.64                | 0.856   |
| Ischemic stroke                          | 0.53 | 0.29–0.99                | 0.046   |
| Heart failure                            | 0.39 | 0.16–0.96                | 0.404   |
| AAA and dissection                       | 0.60 | 0.41–0.87                | 0.007   |
| Pneumonia                                | 0.98 | 0.59–1.64                | 0.940   |
| COPD                                     | 0.85 | 0.54–1.35                | 0.498   |
| Acute respiratory failure                | 2.44 | 1.88–3.18                | <0.001  |
| Vascular disorders of the intestine      | 0.82 | 0.41–1.63                | 0.567   |
| Liver                                    | 0.62 | 0.32–1.20                | 0.158   |
| Renal failure                            | 0.49 | 0.22–1.14                | 0.097   |
| Traumatic intracranial injury            | 1.03 | 0.73–1.46                | 0.863   |
| Other traumas                            | 1.34 | 0.99–1.82                | 0.029   |
| Overdoses                                | 0.08 | 0.02–0.34                | <0.001  |
| Complications of procedures              | 1.80 | 1.33–2.44                | <0.001  |

Most responsible diagnosis groups are compared to a reference group made up of all other diagnoses.

Table 4: Multivariate logistic regression for variables associated with high cost among decedents.

| Characteristics                          | OR   | 95% confidence intervals | P value |
|------------------------------------------|------|--------------------------|---------|
| Age                                      |      |                          |         |
| 18–45                                    | 1.00 |                          |         |
| 46–69                                    | 0.63 | 0.38–1.02                | 0.061   |
| 70–79                                    | 0.63 | 0.37–1.05                | 0.075   |
| 80+                                      | 0.24 | 0.13–0.44                | <0.001  |
| Sex                                      |      |                          |         |
| Male                                     | 1.39 | 1.03–1.87                | 0.032   |
| Female                                   |      |                          |         |

| Elixhauser comorbidity score             |      |                          |         |
| Elixhauser comorbidity score (total)     |      |                          |         |
| Most responsible diagnosis               |      |                          |         |
| Sepsis                                   | 1.21 | 0.80–1.80                | 0.365   |
| Malignancy                               | 1.68 | 1.05–2.67                | 0.030   |
| Subarachnoid hemorrhage                  | 0.35 | 0.08–1.48                | 0.152   |
| Other nontraumatic ICH                   |      |                          |         |
| Ischemic stroke                          |      |                          |         |
| Heart failure                            |      |                          |         |
| AAA and dissection                       |      |                          |         |
| Pneumonia                                |      |                          |         |
| COPD                                     |      |                          |         |
| Acute respiratory failure                |      |                          |         |
| Vascular disorders of the intestine      |      |                          |         |
| Liver                                    |      |                          |         |
| Renal failure                            |      |                          |         |
| Traumatic intracranial injury            |      |                          |         |
| Overdoses                                |      |                          |         |
| Complications of procedures              | 2.85 | 1.52–5.33                | 0.001   |

Most responsible diagnosis groups are compared to a reference group made up of all other diagnoses.
diagnoses associated with high cost was conducted with MRDx, as admitting diagnosis was not available for study. In some cases, the admitting diagnosis may have differed from the postdischarge MRDx.

With respect to cost information, this was a hospital database and thus physician billing is not included. We also did not have data-itemizing procedures such as dialysis and tracheostomy, and although we have the total costs, daily costs were not available for presentation. Furthermore, if patients had multiple admissions during the study period, this analysis only took into account the first admission for consistency. Multiple admissions during the study period may have increased overall costs for an individual patient and moved them into an alternate cost group. This is also a single-centre study, so generalizability to different practice settings may be limited. Additionally, the retrospective study design limits our findings to associations and does not imply causation. Finally, functional data on patients before or after admission were not available, which could affect treatment plans and outcomes.

6. Conclusion

In a population of high-cost ICU patients, we found that the top 10% of patients accounted for half of the cost. Patients in the high-cost group were less likely to be discharged home and more likely to be discharged to long-term care. While cost is associated with LOS, other drivers include younger age or admission for respiratory failure, subarachnoid hemorrhage, or after a procedural complication. Future cost-reduction interventions should incorporate strategies to optimize critical care use among these patients and facilitate efficient transfer out of the ICU when clinically stable.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Disclosure

An earlier version of these data was presented at the American Thoracic Society Annual Meeting in 2017 in Washington, DC. An abstract was subsequently published in the American Journal of Respiratory and Critical Care Medicine, 2017, Volume 195.

Conflicts of Interest

The authors declare that they have no conflicts of interest to disclose.

Acknowledgments

Funding for this project was provided by the Division of Critical Care of the Department of Medicine at the University of Ottawa.

References

[1] Canadian Institute for Health Information, Care in Canadian ICUs, Canadian Institute for Health Information, Toronto, ON, Canada, 2016.
[2] C. Van Walraven, “Trends in 1-year survival of people admitted to hospital in Ontario, 1994-2009,” Canadian Medical Association Journal, vol. 185, no. 16, pp. E755–E762, 2013.
[3] Health Council of Canada, “How do sicker Canadians with chronic disease rate the health care system?,” in Canadian Health Care Matters, Bulletin, Health Council of Canada, Toronto, ON, Canada, 2011.
[4] M. L. Berk and A. C. Monheit, “The concentration of health care expenditures, revisited,” Health Affairs, vol. 20, no. 2, pp. 9–18, 2001.
[5] E. L. Forget, R. Deber, and L. L. Roos, “Medical savings accounts: will they reduce costs?,” Canadian Medical Association Journal, vol. 167, pp. 143–147, 2002.
[6] G. F. Riley, “Long-term trends in the concentration of Medicare spending,” Health Affairs, vol. 26, no. 3, pp. 808–816, 2007.
[7] J. Calver, K. J. Bramweld, D. B. Preen, S. J. Alexia, D. P. Boldy, and K. A. McCaul, “High-cost users of hospital beds in Western Australia: a population-based record linkage study,” Medical Journal of Australia, vol. 184, pp. 393–397, 2006.
[8] S. Rais, A. Nazerian, S. Ardal, Y. Chechulin, N. Bains, and K. Malikov, “High-cost users of Ontario’s healthcare services,” Healthcare Policy, vol. 9, no. 1, pp. 44–51, 2013.
[9] W. P. Wodchis, P. C. Austin, and D. A. Henry, “A 3-year study of high-cost users of health care,” Canadian Medical Association Journal, vol. 188, no. 3, pp. 182–188, 2016.
[10] J. Yip, C. M. Nishita, E. M. Crimmins, and K. H. Wilber, “High-cost users among dual eligibles in three care settings,” Journal of Health Care for the Poor and Underserved, vol. 18, no. 4, pp. 950–965, 2007.
[11] J. M. Welton, A. A. Meyer, L. Mandelkehr, S. M. Fakhry, and S. Jarr, “Outcomes of and resource consumption by high-cost patients in the intensive care unit,” American Journal of Critical Care, vol. 11, pp. 467–473, 2002.
[12] T. W. Noseworthy, E. Konopad, A. Shustack, R. Johnston, and M. Grace, “Cost accounting of adult intensive care: methods and human and capital inputs,” Critical Care Medicine, vol. 24, no. 7, pp. 1168–1172, 1996.
[13] P. E. Ronksley, J. A. McKay, D. M. Kobewka, S. Mulpuru, and A. J. Forster, “Patterns of health care use in a high-cost in-patient population in Ottawa, Ontario: a retrospective observational study,” CMAJ Open, vol. 3, no. 1, pp. E111–E118, 2015.
[14] Data Standards Unit, “Health data branch M of H and L-TC 2014,” in Ontario Case Costing Guide, Version 9.0, Data Standards Unit, Toronto, ON, Canada, 2014.
[15] Canadian Institute for Health Information, Canadian Patient Cost Database Technical Document: MIS Patient Costing Methodology, Canadian Institute for Health Information, Toronto, ON, Canada, 2011.
[16] C. Van Walraven, P. C. Austin, A. Jennings, H. Quan, and A. J. Forster, “A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data,” Medical Care, vol. 47, no. 6, pp. 626–633, 2009.
[17] A. Elixhauser, C. Steiner, D. Robert Harris, and R. M. Coffey, “Comorbidity measures for use with administrative data,” Medical Care, vol. 36, no. 1, pp. 8–27, 1998.
[18] J. F. Dasta, T. P. McLaughlin, S. H. Mody, and C. T. Piech, "Daily cost of an intensive care unit day: the contribution of mechanical ventilation," *Critical Care Medicine*, vol. 33, no. 6, pp. 1266–1271, 2005.

[19] N. Chin-Yee, G. D'Egidio, K. Thavorn, D. Heyland, and K. Kyeremanteng, "Cost analysis of the very elderly admitted to intensive care units," *Critical Care*, vol. 21, p. 109, 2017.

[20] J. M. Kahn, G. D. Rubenfeld, J. Rohrbach, and B. D. Fuchs, "Cost savings attributable to reductions in intensive care unit length of stay for mechanically ventilated patients," *Medical Care*, vol. 46, no. 12, pp. 1226–1233, 2008.

[21] J. Vincent and G. D. Rubenfeld, "Does intermediate care improve patient outcomes or reduce costs?," *Critical Care*, vol. 19, p. 89, 2015.

[22] K. Kyeremanteng, A. Hendin, K. Bhardwaj et al., "Neuro-science intermediate-level care units staffed by intensivists: clinical outcomes and cost analysis," *Journal of Intensive Care Medicine*, article 88506617706651, 2017, In press.

[23] M. Prin and H. Wunsch, "The role of stepdown beds in hospital care," *American Journal of Respiratory and Critical Care Medicine*, vol. 190, no. 11, pp. 1210–1216, 2014.

[24] A. A. Kramer, J. F. Dasta, and S. L. Kane-Gill, "The impact of mortality on total costs within the ICU," *Critical Care Medicine*, vol. 49, no. 9, pp. 1457–1463, 2017.

[25] Y. B. W. E. M. Roos, M. G. W. Dijkgraaf, K. W. Albrecht et al., "Direct costs of modern treatment of aneurysmal subarachnoid hemorrhage in the first year after diagnosis," *Stroke*, vol. 33, no. 6, pp. 1595–1599, 2002.

[26] J. B. Dimick, S. L. Chen, P. A. Taheri, W. G. Henderson, S. F. Khuri, and D. A. J. Campbell, "Hospital costs associated with surgical complications: a report from the private-sector National Surgical Quality Improvement Program," *Journal of the American College of Surgeons*, vol. 199, no. 4, pp. 531–537, 2004.

[27] R. Vonlanthen, K. Slankamenac, S. Breitenstein et al., "The impact of complications on costs of major surgical procedures: a cost analysis of 1200 patients," *Annals of Surgery*, vol. 254, no. 6, pp. 907–913, 2011.

[28] S. V. Arnold, Y. Lei, M. R. Reynolds et al., "Costs of peri-procedural complications in patients treated with transcatheter aortic valve replacement: results from the placement of aortic transcatheter valve trial," *Circulation: Cardiovascular Interventions*, vol. 7, no. 6, pp. 829–836, 2014.

[29] N. Holt, D. Smucker, and J. Hester, "Impact of an inpatient palliative care consult service on length of stay and urgent patient resuscitations in the ICU (727)," *Journal of Pain and Symptom Management*, vol. 41, p. 288, 2011.

[30] K. Kyeremanteng, L.-P. Gagnon, K. Thavorn, D. Heyland, and G. D'Egidio, "The impact of palliative care consultation in the ICU on length of stay: a systematic review and cost evaluation," *Journal of Intensive Care Medicine*, vol. 33, no. 6, pp. 346–353, 2016.

[31] E. Mun, "Trend of decreased length of stay in the intensive care unit (ICU) and in the hospital with palliative care integration into the ICU," *Permanente Journal*, vol. 20, pp. 60–65, 2016.

[32] W. Yu, A. S. Ash, N. G. Levinsky, and M. A. Moskowitz, "Intensive care unit use and mortality in the elderly," *Journal of General Internal Medicine*, vol. 15, no. 2, pp. 97–102, 2000.

[33] L. Fuchs, C. E. Chronaki, S. Park et al., "ICU admission characteristics and mortality rates among elderly and very elderly patients," *Intensive Care Medicine*, vol. 38, no. 10, pp. 1654–1661, 2012.

[34] J. L. Moran, A. R. Peisach, P. J. Solomon, and J. Martin, "Cost calculation and prediction in adult intensive care: a ground-up utilization study," *Anaesthesia and Intensive Care Journal*, vol. 32, pp. 787–797, 2004.